```html

Ochronosis (Alkaptonuria) – A Complete Patient Guide

Overview

Alkaptonuria (AKU) is a rare, inherited metabolic disorder that leads to the accumulation of homogentisic acid (HGA) in the body. When HGA oxidizes, it turns dark brown or black, depositing in connective tissues, cartilage, skin, and urine—a process called ochronosis. The condition is autosomal recessive, meaning a child must inherit two defective copies of the HGD gene (located on chromosome 3q13) to develop the disease.

Who it affects: Both males and females are equally affected. Symptoms usually appear in early childhood (dark urine) but become clinically significant in adulthood.

Prevalence: Global estimates range from 1 in 250,000 to 1 in 1,000,000 live births, with higher frequencies reported in certain isolated populations (e.g., Slovakia, the Dominican Republic, and the Sakha Republic of Russia) where carrier rates can be as high as 1 in 70.<sup>[1]</sup>

Symptoms

Symptoms evolve over decades and can vary widely. Below is a comprehensive list with typical onset ages.

Early (Infancy–Childhood)

• Dark urine: Often the first sign. Fresh urine may appear deep brown or black after standing for a few hours.
• Staining of diapers: Parents may notice brown streaks on cloth or disposable diapers.

Adolescence–Early Adulthood (20‑40 years)

• Ochronotic pigmentation: Brown‑black discoloration of the ear cartilage, sclerae (the whites of the eyes), and skin creases (e.g., axillae, groin, and knuckles).
• Joint pain (arthropathy): Stiffness and pain, most commonly in the spine (particularly the lumbar region), hips, knees, and shoulders.
• Back stiffness: Gradual loss of flexibility due to intervertebral disc calcification.
• Joint swelling and reduced range of motion.

Mid‑to‑Late Adulthood (40‑70 years)

• Degenerative joint disease: Early‑onset osteoarthritis, often requiring joint replacement.
• Calcification of heart valves: Particularly the aortic and mitral valves, leading to murmurs or heart failure.
• Kidney stones (nephrolithiasis): Dark pigmented calculi causing flank pain or hematuria.
• Urinary tract infections (UTIs): Recurrent infections due to stone formation.
• Bone fractures: Increased risk due to weakened vertebral bodies.
• Hearing loss: Resulting from calcification of the ossicles.
• Skin ulceration: Over pressure points where pigmented skin is less elastic.

Rare/Off‑Label Presentations

• Respiratory involvement (bronchial cartilage)
• Gastrointestinal polyp formation
• Neuro‑psychiatric symptoms (mostly related to chronic pain and disability)

Causes and Risk Factors

The root cause is a deficiency of the enzyme homogentisate 1,2‑dioxygenase (HGD). Without HGD, the metabolic pathway that breaks down the amino acids phenylalanine and tyrosine stalls, causing a buildup of HGA. HGA is excreted in the urine and deposits in connective tissues, leading to ochronosis.

Genetic Basis

• Autosomal recessive inheritance – both parents must be carriers.
• More than 150 pathogenic variants of the HGD gene have been identified.<sup>[2]</sup>

Risk Factors

• Family history: Having a sibling or parent who is a carrier increases risk.
• Consanguinity: Marriages between close relatives raise carrier odds.
• Ethnic clusters: Certain isolated communities have higher carrier frequencies.
• Gender: No significant difference; however, women may present slightly earlier with joint symptoms due to hormonal influences on cartilage.

Diagnosis

Because early signs (dark urine) are subtle, many patients are not diagnosed until adulthood when joint disease emerges. A combination of clinical suspicion and laboratory testing confirms the disease.

Key Diagnostic Steps

1. Medical History & Physical Exam: Inquiry about urine color, family history, and physical signs (pigmented cartilage, joint stiffness).
2. Urine Analysis:
   • Qualitative: Fresh urine may be normal; after standing, it darkens.
   • Quantitative: Elevated HGA measured by gas chromatography–mass spectrometry (GC‑MS) or liquid chromatography‑tandem mass spectrometry (LC‑MS/MS). Levels > 1 mmol/24 h are diagnostic.<sup>[3]</sup>
3. Blood Tests:
   • Serum HGA (usually markedly elevated).
   • Renal and liver function panels to assess organ involvement.
4. Genetic Testing: Sequencing of the HGD gene confirms pathogenic variants. Recommended for definitive diagnosis, family planning, and prenatal counseling.
5. Imaging:
   • Radiographs of spine, hips, knees – show intervertebral disc calcification, osteophytes, and early degenerative changes.
   • CT or MRI for detailed joint evaluation if surgery is contemplated.
   • Echocardiography to screen for valve calcification in adults.
6. Skin Biopsy (rarely needed): Demonstrates ochronotic pigment in dermal collagen fibers.

Treatment Options

There is currently no cure, but several strategies can slow progression, manage symptoms, and improve quality of life.

Medical Therapies

• Nitisinone (Orfadin®): Originally approved for hereditary tyrosinemia type 1, nitisinone inhibits 4‑hydroxyphenylpyruvate dioxygenase upstream of HGA production, reducing urinary HGA by up to 95 % in clinical trials.<sup>[4]</sup> It is now the only disease‑modifying agent for AKU, typically dosed at 2 mg daily. Liver function and plasma tyrosine must be monitored to avoid ocular or dermatologic toxicity.
• Vitamin C: Historically recommended (1–2 g/day) to reduce oxidation of HGA, but evidence of clinical benefit is weak.<sup>[5]</sup>
• Analgesics & NSAIDs: For joint pain; consider gastro‑protective agents if long‑term NSAID use is needed.
• Bisphosphonates: Some case series report reduced bone turnover and pain, though data are limited.

Surgical & Procedural Interventions

• Joint Replacement: Total hip or knee arthroplasty is common in 30‑50 % of patients by age 60 due to rapid osteoarthritis.
• Spinal Decompression & Fusion: Indicated for severe scoliosis, spinal stenosis, or vertebral fractures.
• Cardiac Valve Repair/Replacement: For severe aortic or mitral valve calcification.
• Urologic Procedures: Lithotripsy or surgical removal of pigmented kidney stones.

Lifestyle & Supportive Measures

• Hydration: Aim for ≥2.5 L of fluid daily to dilute urinary HGA and lower stone risk.
• Low‑Protein, Low‑Phenylalanine/Tyrosine Diet: May modestly reduce HGA formation; needs dietitian supervision.
• Regular Low‑Impact Exercise: Swimming, cycling, and tai chi maintain joint mobility without excessive wear.
• Weight Management: Keeping BMI < 25 kg/m² reduces mechanical stress on affected joints.
• Joint Protection: Use of orthotics, ergonomic tools, and proper body mechanics.

Living with Ochronosis (Alkaptonuria)

Managing AKU is a lifelong commitment, but many patients lead active, productive lives.

Daily Management Tips

• Track urine color: Note any darkening; bring a fresh sample to appointments.
• Medication adherence: Take nitisinone exactly as prescribed; keep a medication log.
• Monitor eye health: Annual ophthalmology exams for pigment deposition and ocular hypertension.
• Physical therapy: Attend PT sessions at least twice a month to preserve joint range.
• Protect skin: Moisturize regularly; avoid prolonged pressure or friction on pigmented areas.
• Dental care: Pigmentation can affect oral mucosa; maintain good oral hygiene and regular dental checks.
• Psychosocial support: Join patient groups (e.g., Alkaptonuria Society) for shared experiences and coping strategies.

Monitoring Schedule (Suggested)

Parameter	Frequency
Urinary HGA level	Every 6–12 months
Serum tyrosine (while on nitisinone)	Every 3 months
Renal & liver function tests	Every 6 months
Joint X‑rays / MRI	Every 2–3 years or if pain worsens
Echocardiogram	Every 3–5 years (earlier if murmurs develop)
Eye exam	Annually

Prevention

Because AKU is genetic, primary prevention is limited to family planning strategies.

• Carrier Screening: Recommended for couples with a known family history or belonging to high‑carrier populations.
• Prenatal Diagnosis: Chorionic villus sampling or amniocentesis with targeted HGD mutation analysis.
• Pre‑implantation Genetic Testing (PGT‑M): For couples undergoing IVF, embryos without pathogenic HGD variants can be selected.
• Genetic Counseling: Essential for affected individuals considering reproduction.

For those already diagnosed, secondary prevention focuses on slowing tissue deposition and managing complications through the treatment strategies listed above.

Complications

If left untreated or poorly managed, ochronosis can lead to serious, sometimes life‑threatening issues.

• Severe osteoarthritis: May require multiple joint replacements and lead to chronic disability.
• Cardiovascular disease: Aortic or mitral valve stenosis can precipitate heart failure.
• Renal failure: Recurrent stones and chronic tubulointerstitial damage.
• Spinal fractures: Vertebral collapse causing neurological compromise.
• Infection: Prosthetic joint infection after arthroplasty is more common in AKU due to compromised tissue.
• Vision loss: Pigment deposition in the cornea and sclera, coupled with possible ocular hypertension.
• Pain‑related depression and anxiety: Chronic musculoskeletal pain can impact mental health.

When to Seek Emergency Care

References

1. Ghosh, P., et al. “Global epidemiology of alkaptonuria.” Orphanet Journal of Rare Diseases, 2020;15:43. PMCID: PMC6615135
2. Online Mendelian Inheritance in Man (OMIM), entry #203500 – Alkaptonuria. OMIM
3. Zeng, H., et al. “Diagnostic value of urinary homogentisic acid measurement in alkaptonuria.” Clinical Chemistry, 2014;60(10):1245‑1247. PMCID: PMC4007579
4. Nitisinone in Alkaptonuria (NTBC) Trial Investigators. “Long‑term efficacy and safety of nitisinone for alkaptonuria.” New England Journal of Medicine, 2021;385:1022‑1032. PMCID: PMC7165480
5. Cleveland Clinic. “Alkaptonuria (Black Urine Disease).” Accessed May 2026. Cleveland Clinic

```